ThromboGenics Opens New U.S. Headquarters
U.S. Organization Continues to Build Ahead of Ocriplasmin’s Planned Launch
ThromboGenics NV announced the opening of its new U.S headquarters. The facility which is situated in Iselin, New Jersey, is the new home to the Company’s U.S. organization which is led by Dr. David Pearson, Head of U.S. Country Operations. ThromboGenics has been growing its U.S. team in recent months building its marketing, medical, commercial, market access and regulatory expertise ahead of the Company’s planned launch of its lead product ocriplasmin.
ThromboGenics intends to resubmit a BLA for ocriplasmin in the U.S. before the end of April 2012 and expects the product to be granted Priority Review by the FDA. Ocriplasmin will be filed for the treatment of symptomatic vitreomacular adhesion (VMA) including macular hole.
Dr Patrik De Haes, CEO of ThromboGenics, commented: “The opening of our new U.S Headquarters is an important step as we build the first-class organization that we need to successfully launch ocriplasmin in the world’s largest healthcare market. We remain on track to resubmit a BLA for ocriplasmin before the end of April for Priority Review. Our U.S. team is expecting a very exciting and highly productive period as it prepares for the anticipated approval of ocriplasmin by the end of 2012.”
As a result of its decision to locate its headquarters in Iselin, ThromboGenics will benefit from a Business Employment Incentive grant from the New Jersey Economic Development Authority whose value could exceed $1.0 million over a multi-year period.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Researchers work to create biodegradable bioplastics from food waste - Use of microorganisms to convert food waste into fats, which are then processed into bioplastics
Evotec and LEO Pharma form drug discovery alliance targeting dermatological conditions
Adventus Group Establishes Joint Venture for European Expansion with S&B Industrial Minerals
Analytik Jena AG establishes subsidiary in Thailand
Study suggests early exposure to antibiotics may impact development, obesity
Pharming's Ruconest(TM) for HAE granted European Marketing Authorization
Start-up receives €24 million for the development of a potential COVID-19 treatment - EIB backs Atriva Therapeutics
Access and SpePharm Announce Licensing of MuGard for Europe - SpePharm Will Market MuGard in Europe for the Treatment of Oral Mucositis
Sartorius Stedim Biotech and Bosch Packaging Technology Announce Global Collaboration
